Objective Depression is a leading cause of disability and produces a greater decrement in health than other common chronic diseases such as angina, arthritis, asthma and diabetes. In Europe, it is estimated that 7.2% of the disease burden is caused by depression with associated costs of €118 billion. It generally takes months before clinicians are able to identify an effective antidepressant treatment for individual patients and during this period a patients’ ability to work and function socially is severely impaired by their illness. We will address this problem using the Primary Care –Emotional Test Battery (PC-ETB) a medical device that is sensitive to changes in negative emotional bias, an early biomarker for the effectiveness of antidepressant treatment. Identifying early, rather than late in treatment, if an antidepressant is working will significantly reduce the time required for the patient to get better and return to normal life. The PC-ETB has been developed from a more extensive product battery that we provide to the pharmaceutical industry for drug development. In Phase 1 we will: (i) Assess the feasibility of using the PC-ETB in primary care in Europe; (ii) Determine how to set up a multinational medical device clinical investigation in Europe; (iii) Expand a health economic assessment conducted in the UK to include other major European countries and demonstrate the healthcare and societal benefits across Europe; (iv) Develop a commercialisation strategy across the major European countries by conducting a market research assessment of the market size, route to adoption, pricing and reimbursement mechanisms. In Phase 2 of the project we will conduct clinical validation of multi-lingual versions of the PC-ETB in a number of European countries. This innovative project is designed to complete the clinical validation of the PC-ETB and enable its launch as an internet delivered product to improve the management and treatment of depression across the European market. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health scienceshealth scienceshealth care serviceseHealthmedical and health sciencesclinical medicinepneumologyasthmamedical and health sciencesclinical medicinerheumatologymedical and health sciencesclinical medicineendocrinologydiabetes Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Call for proposal H2020-SMEInst-2014-2015 See other projects for this call Sub call H2020-SMEINST-1-2014 Funding Scheme SME-1 - SME instrument phase 1 Coordinator P1VITAL LIMITED Net EU contribution € 50 000,00 Address MANOR HOUSE HOWBERY PARK OX10 8BA Wallingford United Kingdom See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00